Lumefantrine
Coartem (lumefantrine) is a small molecule pharmaceutical. Lumefantrine was first approved as Coartem on 2009-04-07. It is used to treat falciparum malaria and malaria in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Combinations
Coartem
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| coartem | New Drug Application | 2024-07-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| malaria | EFO_0001068 | D008288 | B54 |
| falciparum malaria | EFO_0007444 | D016778 | B50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
239 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 21 | 27 | 53 | 82 | 53 | 224 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 4 | 18 | 26 | 36 | 19 | 94 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 1 | 1 | 2 | 6 | 4 | 14 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | 1 | 6 | — | 9 |
| Infections | D007239 | EFO_0000544 | — | 2 | — | — | 2 | 2 | 6 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | 3 | 2 | 5 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | 1 | 3 | 4 |
| Hiv | D006678 | — | — | 2 | — | — | 1 | — | 3 |
| Communicable diseases | D003141 | — | — | 1 | — | — | 1 | 1 | 3 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | 1 | — | 1 | — | 2 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fever | D005334 | HP_0001945 | R50.9 | — | — | 1 | — | 2 | 3 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | 2 | — | — | 2 |
| Covid-19 | D000086382 | — | — | — | — | 1 | — | — | 1 |
| Disease susceptibility | D004198 | — | — | — | — | 1 | — | — | 1 |
| Asymptomatic diseases | D058070 | — | — | — | 1 | 1 | — | — | 1 |
| Blister | D001768 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 2 | — | — | — | 4 |
| Combination drug therapy | D004359 | — | — | 2 | 1 | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | 1 | — | — | — | 2 |
| Schistosomiasis haematobia | D012553 | EFO_0007530 | B65.0 | — | 1 | — | — | — | 1 |
| Ebola hemorrhagic fever | D019142 | EFO_0007243 | A98.4 | — | 1 | — | — | — | 1 |
| Virus diseases | D014777 | — | B34 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 1 | — | — | — | 4 | 5 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | 2 | — | — | — | — | 2 |
| Parasitemia | D018512 | — | — | 2 | — | — | — | — | 2 |
| Protozoan infections | D011528 | — | B50-B64 | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
| Severe acute malnutrition | D000067011 | — | — | — | — | — | — | 1 | 1 |
| Hyperthermia | D000084462 | — | — | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
| Chemoprevention | D018890 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lumefantrine |
| INN | lumefantrine |
| Description | Lumefantrine is a member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria. It has a role as an antimalarial. It is a tertiary amine, a member of monochlorobenzenes, a secondary alcohol and a member of fluorenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 82186-77-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL38827 |
| ChEBI ID | 156095 |
| PubChem CID | 6437380 |
| DrugBank | DB06708 |
| UNII ID | F38R0JR742 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,918 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
374 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use